Novo Nordisk reports positive childhood obesity trial results

The third phase of the STEP Young trial demonstrated that weekly treatment with semaglutide, combined with a low-calorie diet and increased physical activity, helps reduce body mass index (BMI) in children aged 6 to 12 years with severe obesity. It was observed that approximately 40.4% of the children who received the treatment were no longer classified as obese after 68 weeks, compared to none in the placebo group. The safety results were favorable, showing no new risks or adverse effects on growth during the study period. These findings are significant as they expand treatment options for childhood obesity and underscore the role of semaglutide in improving weight management and reducing potential health complications associated with obesity in children.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل